ASCO Annual Meeting | Conference

FDA and Industry Collaborating to Prevent Cancer Drug Shortages

June 5th 2012

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer

June 5th 2012

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients

June 4th 2012

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. Demetri Discusses Regorafenib for GIST Patients

June 4th 2012

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST

June 4th 2012

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Afatinib Prolongs PFS in Lung Cancer Trial

June 4th 2012

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients

June 3rd 2012

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial

June 3rd 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Rummel on Treanda Plus Rituxan in Indolent Lymphoma

June 3rd 2012

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer

June 3rd 2012

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

Bendamustine Superiority in Lymphoma Regimen Confirmed

June 3rd 2012

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival

June 3rd 2012

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

June 2nd 2012

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer

June 2nd 2012

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows

June 2nd 2012

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients

June 2nd 2012

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

June 2nd 2012

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Rotkowitz on BRAF/MEK Combination Side Effects

June 1st 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

NEXT PAGE
PREVIOUS PAGE